Stay updated with breaking news from Bio techne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to the report published by Allied Market Research, the Australia and New Zealand fetal bovine serum market was pegged at $20 million in 2020 and is estimated to hit $35 million by 2030, registering a CAGR of 5.2% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top. ....
Benchmark reaffirmed their buy rating on shares of Bio-Techne (NASDAQ:TECH – Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $95.00 target price on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada reduced their price objective on […] ....
Bio-Techne (NASDAQ:TECH – Get Free Report) had its target price hoisted by equities research analysts at Robert W. Baird from $73.00 to $81.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would suggest a potential upside […] ....
Bio-Techne (NASDAQ:TECH – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03, Briefing.com reports. Bio-Techne had a net margin of 19.58% and a return on equity of 14.21%. The firm had revenue of $303.43 million for the […] ....
Bio-Techne (NASDAQ:TECH – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Benchmark in a research note issued on Thursday, Benzinga reports. They presently have a $95.00 price target on the biotechnology company’s stock. Benchmark’s price target points to a potential upside of 27.86% from the company’s current price. TECH has […] ....